Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 randomised, open-label, multi-centre ascending dose study of the efficacy, safety and tolerability of I-040302 versus control injection (bone marrow aspirate or steroids) in children and young adults with solitary bone cysts

Next Previous
X
Search
Trial Profile

A phase 2 randomised, open-label, multi-centre ascending dose study of the efficacy, safety and tolerability of I-040302 versus control injection (bone marrow aspirate or steroids) in children and young adults with solitary bone cysts

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KUR 112 (Primary) ; KUR 112 (Primary) ; Methylprednisolone
  • Indications Bone cysts
  • Focus Therapeutic Use

    • Most Recent Events

    • 30 Jul 2022 Status changed from withdrawn prior to enrolment to completed.
    • 16 Jul 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 15 Mar 2012 Planned initiation date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top